of Health, pharmaceutical companies are virtually the only current source of funding of large-outcome trials. Their results should be published in peer-reviewed journals, but caution must be taken in accepting their results to be more than marketing tools. Their study design should be independently reviewed before initiation, and rigorous examination of their results should be provided by peer reviewers with statistical expertise.Acknowledgments DisclosuresNone.Footnotes The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.ReferencesBeckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, Stoyanovsky V, Antikainen RL, Nikitin Y, Anderson C, Belhani A, Forette F, Rajkumar C, Thijs L, Banya W, Bulpitt CJ. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008; 358: 18871898.[Abstract/Free Full Text]The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008; 358: 15471559.[Abstract/Free Full Text]Jamerson KA, Bakris GL, Dahlof B, Pitt B, Velazquez E, Weber MA, ACCOMPLISH Investigators. Avoiding cardiovascular events through combination therapy in patients living with systolic hypertension, the early termination of the ACCOMPLISH Trial for Efficacy. 57th Annual Scientific Session of the American College of Cardiology; Late Breakers (plus oral presentation; abstract 407-2); March 29, 2008; Chicago, IL.Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin- converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet. 2003; 361: 117124.[CrossRef][Medline] [Order article via Infotrieve]Khosla N, Bakris G. Lessons learned from recent hypertension trials about kidney disease. Clin J Am Soc Nephrol. 2006; 1: 229235.[Free Full Text]Kunz R, Wolbers M, Glass T, Mann JFE. The COOPERATE trial: a letter of concern. Lancet. 2008; 371: 1575.[CrossRef][Medline] [Order article via Infotrieve]Vasan RS, Beiser A, Seshadri S, Larson MG, Kannel WB, D'Agostino RB, Levy D. Residual lifetime risk for developing hypertension in middle-aged women and men: the Framingham Heart Study. JAMA. 2002; 287: 10031010.[Abstract/Free Full Text]Bulpitt CJ, Beckett NS, Cooke J, Dumitrascu DL, Gil-Extremera B, Nachev C, Nunes M, Peters R, Staessen JA, Thijs L; Hypertension in the Very Elderly Trial Working Group. Results of the pilot study for the Hypertension in the Very Elderly Trial. J Hypertens. 2003; 21: 24092417.[CrossRef][Medline] [Order article via Infotrieve]Kehoe PG, Wilcock GK. Is inhibition of the renin-angiotensin system a new treatment option for Alzheimers disease? Lancet. 2007; 6: 373378.[CrossRef]The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000; 342: 145153.[Abstract/Free Full Text]McMurray JJV. ACE inhibitors in cardiovascular disease unbeatable? N Engl J Med. 2008; 358: 16151616.[Free Full Text]Matchar DB, McCrory DC, Orlando LA, Patel MR, Patel UD, Patwardhan MB, Powers B, Samsa GP, Gray RN. Systemic review: comparative effectiveness of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med. 2008; 148: 1629.[Abstract/Free Full Text]Jamerson K, Bakris GL, Dahlof B, Pitt B, Velazquez E, Gupte J, Lefkowitz M, Hester A, Shi V, Kjeldsen SE, Cushman W, Papademetriou V, Weber M, for the Accomplish Investigators.